Plastic Surgery
Audio Summaries

A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis

The authors aimed to evaluate the efficacy and safety of a 6-month treatment regimen for pulmonary rifampicin-resistant tuberculosis compared to the standard 9-month treatment in South Africa. The study found that the 6-month regimen was noninferior in achieving successful treatment outcomes and had a similar safety profile to the standard regimen. This suggests that the shorter treatment duration may be a viable alternative for managing rifampicin-resistant tuberculosis.

Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

The authors aimed to evaluate the long-term outcomes of anti-CD19 CAR T-cell therapy (tisagenlecleucel) in patients with relapsed or refractory B-cell non-Hodgkin lymphomas over a median follow-up of 10.1 years. They found that approximately 32% of patients with large B-cell lymphoma and 47% with follicular lymphoma achieved lymphoma-free survival, with a notable persistence of B-cell aplasia in long-term responders. The study highlights the potential for durable remissions in this patient population, despite some risks of non-relapse-related mortality and secondary cancers.

Prevention and Treatment of Peanut Allergy

This paper investigates the effectiveness of early peanut protein introduction and immunotherapy in preventing and treating peanut allergy. The authors find that introducing peanut protein early significantly reduces allergy prevalence, with optimal prevention strategies differing for low and high-risk infants. Additionally, they highlight that immunotherapy is more effective when started in younger children, emphasizing the critical need for early intervention.

Management of Differentiated Thyroid Cancer

The authors aim to establish a comprehensive framework for the risk-adapted management of differentiated thyroid cancer, emphasizing the importance of dynamic risk stratification throughout the patient's clinical journey. They explore how clinicopathological staging and molecular risk characterization inform personalized management plans, particularly in the contexts of active surveillance for low-risk cases and treatment options for advanced disease. The paper illustrates therapeutic decision-making processes that balance risks, benefits, and patient preferences to enhance management strategies.

Cefazolin for Methicillin-Susceptible <em>Staphylococcus aureus</em> Bacteremia

The authors aimed to determine whether cefazolin is noninferior to antistaphylococcal penicillins (flucloxacillin or cloxacillin) in treating methicillin-susceptible *Staphylococcus aureus* bacteremia, particularly regarding 90-day mortality rates. The study found that cefazolin demonstrated noninferiority in mortality outcomes and was associated with a lower incidence of acute kidney injury compared to the penicillin group.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma

The authors aimed to evaluate the efficacy of talquetamab in combination with daratumumab and pomalidomide (Tal-DP) compared to daratumumab plus pomalidomide and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma. The phase 3 trial demonstrated that both Tal-DP and talquetamab plus daratumumab (Tal-D) significantly improved progression-free survival and overall response rates compared to DPd, indicating a promising treatment option for this patient population.

Lonvoguran Ziclumeran - In Vivo CRISPR Gene Editing in Hereditary Angioedema

The authors aimed to evaluate the efficacy and safety of lonvoguran ziclumeran (lonvo-z), an investigational CRISPR-based gene-editing treatment, in reducing the frequency of attacks in patients with hereditary angioedema due to C1 inhibitor deficiency. In a phase 3 trial, a single intravenous infusion of lonvo-z significantly decreased the monthly attack rate compared to placebo, with a relative reduction of 87%. While adverse events were reported in both groups, no serious complications occurred in the lonvo-z group, indicating a favorable safety profile.

Sodium Bicarbonate for Critically Ill Adults with Metabolic Acidosis and Shock

The study aimed to determine whether sodium bicarbonate administration in critically ill adults with metabolic acidosis receiving vasopressors would reduce the risk of major adverse kidney events within 30 days compared to a placebo. The results indicated no significant difference in the occurrence of these events between the sodium bicarbonate group and the placebo group, suggesting that sodium bicarbonate does not provide a renal protective benefit in this patient population.

Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease

This study evaluates the efficacy and safety of exagamglogene autotemcel (exa-cel), a gene-editing cell therapy, in children aged 5 to 11 with transfusion-dependent β-thalassemia or sickle cell disease. The authors aimed to determine whether exa-cel could achieve transfusion independence in β-thalassemia patients and freedom from severe vaso-occlusive crises in sickle cell disease patients over a follow-up period of at least 16 months. Results indicated that all evaluated children achieved the desired clinical outcomes, although all experienced significant adverse events related to the treatment.

The Likelihood of Future Dupuytren Disease Intervention After Initial Treatment in the Same Digit, Another Digit, and Contralateral Hand

The authors aimed to determine the likelihood of future interventions for Dupuytren contracture after initial treatment in one digit, as well as identify predictive factors influencing these outcomes. They found that within five years, 42% of patients required additional treatment, with significant associations linked to factors such as age, smoking status, and the presence of initially untreated contractures. These findings highlight the need for tailored patient counseling based on individual risk factors.